KPRX
Kiora Pharmaceuticals Inc

4,084
Loading...
Loading...
News
all
press releases
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know
Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Encinitas, California--(Newsfile Corp. - April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor...
Newsfile Corp. - News Releases·1y ago
News Placeholder
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ('Kiora' or the 'Company') announced that additional data from the ABACUS-1 trial has been...
Newsfile Corp. - News Releases·1y ago
News Placeholder
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ('Kiora' or...
Newsfile Corp. - News Releases·1y ago
News Placeholder
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 3.8%
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX Get Free Report) dropped 3.8% during mid-day trading on Thursday . The company traded as low as $0.58 and last traded at $0.58. Approximately 78,144...
Ticker Report·1y ago
News Placeholder
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ('Kiora' or the 'Company') announced the publication of results from a Phase 1 double-masked...
Newsfile Corp. - News Releases·2y ago
News Placeholder
HC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To Know
Latest Ratings for KPRX DateFirmActionFromTo Jan 2022Maxim GroupInitiates Coverage OnBuy View More Analyst Ratings for KPRX View the Latest Analyst Ratings read more...
Benzinga·2y ago
News Placeholder
Kiora Pharmaceuticals price target lowered by $1.50 at H.C. Wainwright, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million...
Newsfile Corp. - News Releases·2y ago
News Placeholder
Kiora Pharmaceuticals Inc trading resumes
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago

Latest KPRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.